A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-On to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes
This 52-week, multinational, randomized, open-label, non-inferiority trial compared the efficacy and safety of insulin detemir and insulin glargine as add-on therapy to oral glucose-lowering drugs in insulin-naive adults with type 2 diabetes. A total of 582 participants were randomized to receive either insulin detemir or insulin glargine once daily, titrated
June 26, 2025
No Comments